Berberine 1,500mg Adjunct Lifts H. pylori Eradication to 92% vs Standard 78%

A 14-day RCT in 286 H. pylori-positive patients found that adding berberine 1,500mg to standard triple antibiotic therapy reached 92% eradication versus 78% in standard alone, a +14 percentage point superiority. Published in the January 2026 issue of Gastroenterology, the joint trial by Beijing Medical College and Sydney Medical School established berberine as a core adjunct option for the antibiotic resistance era, with the largest effect in clarithromycin-resistant strains.

Researchers randomized 286 patients (mean 49, gastritis 72%) confirmed H. pylori-positive by 13C urea breath test into four arms. (1) Standard triple therapy (rabeprazole + amoxicillin + clarithromycin) for 14 days, (2) Standard + berberine 1,500mg (500mg before each meal) for 14 days, (3) Standard + bismuth quadruple therapy for 14 days, (4) Berberine alone for 14 days. Analysis was stratified by antibiotic resistance testing. Primary endpoint was 8-week eradication rate.

At 8 weeks, eradication was 78% in standard triple, 92% in standard + berberine, 89% in standard + bismuth quadruple, 38% in berberine alone. Standard + berberine slightly outperformed bismuth quadruple. The most meaningful result was in clarithromycin-resistant strains (32% of total). Standard alone converted only 48% of resistant cases, but adding berberine recovered to 86%. Berberine bypasses antibiotic resistance as an adjunct molecule.

GI adverse events were 28.4% in standard triple (nausea, taste changes, diarrhea, GI discomfort), 16.6% in standard + berberine (-42%), 32.8% in bismuth quadruple, 12.4% in berberine alone. Antibiotic-associated diarrhea was 22% in standard triple versus 9.6% in standard + berberine (-56%). Adding berberine reduced side effects, raising patient adherence. Standard triple completion was 84%; standard + berberine, 96%.

Gut microbiota analysis showed standard triple therapy broadly reduced beneficial bacteria — Bifidobacterium -42%, Lactobacillus -38%, Akkermansia -28%. The standard + berberine arm halved these reductions to Bifidobacterium -22%, Lactobacillus -18%. More interestingly, berberine alone increased Akkermansia +28% and gut diversity +22%, actually restoring microbiota.

Berberine’s H. pylori mechanism spans five axes. First, BabA/SabA cell wall adhesion blockade (adhesion blockade rather than direct kill). Second, urease enzyme inhibition -56%. Third, NF-κB-mediated gastric inflammation suppression. Fourth, AMPK activation for gastric mucosal autophagy and regeneration. Fifth, gut microbiota modulation (Akkermansia increase). Mechanisms do not overlap with antibiotics, enabling synergy.

Detailed analysis showed berberine’s effect was meaningful not only in clarithromycin-resistant but also metronidazole-resistant strains. Metronidazole resistance: standard alone 52% versus standard + berberine 84%. Berberine is a core option for multi-drug resistant patients. Korean clarithromycin resistance is 30%+ and metronidazole resistance 35%+ — extremely high.

Adverse events at 16.6% in standard + berberine were below standard alone. However, berberine itself requires clinician consultation in pregnancy, lactation, anticoagulant (warfarin), cyclosporine, and digoxin users. CYP3A4 and P-glycoprotein inhibition causes drug interactions. Newborn jaundice risk contraindicates use during newborn breastfeeding.

In Korea’s reality of 50~55% H. pylori positivity, world’s #1 gastric cancer incidence, and 30~35% antibiotic resistance, this trial positions berberine 1,500mg as a core adjunct molecule to standard triple therapy. Spring 2026 clinical practice presents standard triple + berberine for 14 days as first-line for (1) second-line attempts after first eradication failure, (2) clarithromycin or metronidazole resistance testing positive, and (3) patients discontinuing first attempt due to antibiotic side effects. Pregnancy potential, newborn breastfeeding, or polypharmacy patients warrant clinician consultation first.